ライフサイエンスコーパス: package insert

1 this information was added to the linezolid package insert.

2 cts of this drug which was not listed by its package insert.

3 try for ibritumomab tiuxetan and the product package insert.

4 some of which are currently reflected in the package insert.

5 impairment were added to the zoledronic acid package insert.

6 n response or lack thereof should follow the package insert.

7 included in the 'indications' portion of the package insert.

8 ol procedures outlined in the manufacturer's package insert.

9 s for the bortezomib dosages were within the package insert.

10 correctly diagnosed than is suggested by the package inserts.

11 ng and after PCI, defined in accordance with package inserts.

12 for tuberculosis diagnostics reported in 19 package inserts against estimates in published meta-anal

13 provided by the test manufacturer in product package inserts, also known as instructions for use (IFU

14 the reporting of diagnostic accuracy data in package inserts and policy makers should demand independ

15 patient labeling (Medication Guides, Patient Package Inserts and/or Instructions for Use), and/or car

16 who received dexamethasone according to the package insert) and granisetron (2 mg orally) on days 2-

17 The FDA package insert, and in some cases PubMed, of each identi

18 nts taking antidepressants; a boxed warning, package insert, and medication guide were implemented in

19 andard procedure, based on the XR-naltrexone package insert (approximately 5-day buprenorphine taper

20 m the drug-effect relationships found in FDA package inserts as recorded in the SIDER database.

21 upplemental Assay as published in that assay package insert (Bio-Rad Laboratories, Hercules, CA), the

22 eportedly produces alopecia according to the package insert, but clinical and histologic descriptions

23 filled the criteria for SL8 according to the package insert, but only 193 (57.2%) were eventually tre

24 red renal function are reflected in a recent package insert change by the Food and Drug Administratio

25 e color results (negative result but with no package insert color visible), and 8,234 specimens were

26 Drug labels, or prescribing information or package inserts, describe ADRs.

27 Our survey of FDA drug package insert documents and other resources for 224 neu

28 Folic acid package inserts, early editions of hematology textbooks,

29 The information provided in the package insert facilitates physician education and provi

30 approved drugs, clinicians must consult the package insert for detailed prescribing information, lis

31 t use of cerivastatin and gemfibrozil to the package insert for more than 18 months.

32 We searched company websites for package inserts for RATs that were included in the July

33 ssionals and the public should be aware that package inserts for SARS-CoV-2 RATs might provide an ove

34 es in published meta-analyses and found that package inserts generally report overoptimistic accuracy

35 f the 70 FDA new or revised labels, only six package inserts include PRO data.

36 F BDG testing was performed according to the package insert instructions for serum samples, and resul

37 ly identical to those obtained following the package insert instructions.

38 end including a statement within the Patient Package Inserts/Instructions for use.

39 use not described in the indications of the package insert is considered 'off-label'.

40 eri test performance published through 1998, package insert labeling from FDA-cleared test kits for B

41 definitive geriatric dose recommended in the package inserts made available to the public.

42 According to package inserts, metformin is contraindicated in diabeti

43 The package inserts of all approved antipsychotics contain p

44 Laboratorians and clinicians often rely on package inserts of diagnostic tests to assess their accu

45 However, package inserts of most tests approved by the U.S. Food

46 edict DDIs by integrating SEs extracted from package inserts of prescription drugs, SEs extracted fro

47 cluded in calculations were derived from the package insert or original trial publication.

48 n available regarding dose reductions in the package insert or trial publication.

49 3 parkinsonism in the idecabtagene vicleucel package insert, our findings support close neurological

50 ADR information for oncology drugs from package insert (PI) revisions, so-called Dear Doctor let

51 ronic databases, print references, published package inserts, product packages, and direct communicat

52 o impact performance indices compared to the package insert protocol (P >/= 0.31), provided accurate

53 Package insert protocol instructions were followed.

54 The US EFV package insert recommends an EFV dose increase for patie

55 The current package insert recommends an examination period of 3 day

56 In this study, we systematically collected package insert-reported AEs associated with CVDs used in

57 ty control (QC) ranges listed in the product package insert require an adjusted range by approximatel

58 ALIPER and PEDREF studies and manufacturers' package inserts shows good agreement of reference limits

59 specimen stability for use beyond the Aptima package insert specifications for temperature and durati

60 Package insert warnings and precautions for omadacycline

61 Compared with the current package insert, we found differences in median absorbed

62 Bortezomib therapy was administered per package insert with plasmapheresis performed immediately